Cell Source Overview
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented Veto Cell technology enables safe and selective tuning of immune responses. Veto Cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a proprietary mix of off-the-shelf, FDA-approved cytokines that change their characteristics and activate their inherent attacker-blocking capability. Once reintroduced into the body intravenously, they can perform a number of important functions. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating blood cancers such as lymphoma and nonmalignant congenital diseases such as sickle cell anemia.
Latest News
growth-positive
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Cell Source, Inc. presented promising preclinical findings at the 2024 American Society of Hematology Annual Meeting, showcasing their Veto Cell technologys ability to overcome NK cell-mediated rejection, a significant barrier in allogeneic cell therapy. This innovation could lead to safer, less costly, and more scalable off-the-shelf CAR-T therapies. The study demonstrated that Veto Tcm cells can suppress NK cell activity without adverse effects, enhancing the safety and efficacy of allogeneic CAR-T therapies. These findings align with Cell Sources vision of advancing immune tolerance to facilitate safer mismatched donor stem cell transplants and organ transplantation. The research represents a significant step towards overcoming challenges in developing off-the-shelf CAR-T cell therapies, a critical area in cancer immunotherapy.
growth-positive
Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial
Cell Source, Inc. announced positive interim results from its Phase 1/2 clinical trial using its Veto Cell technology for stem cell transplants. Conducted at The University of Texas MD Anderson Cancer Center, the trial involved 15 patients and demonstrated both safety and efficacy, with no severe graft-versus-host disease or toxicity linked to Veto Cells. This breakthrough suggests a safer, more patient-friendly approach to stem cell therapy, potentially transforming treatment for various hematologic conditions. The results were previously presented at the American Society for Hematology Annual Meeting. The findings highlight the potential of Veto Cells to improve access to life-saving transplants, aligning with the strategic goals of Cell Source. The success in this area mirrors the market potential seen in companies like Kite Pharma and Juno Therapeutics, which were acquired for substantial amounts following similar clinical achievements.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21.54M |
| Last funding | $21.54M |
| Stage | Public |
| Rounds | 1 |
| Investors | 0 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | cell-source.com |
Locations
Kinneret St 5, Bnei Brak, Israel
57 West 57th Street, New York, NY 10019, USA
Photos & Videos
2 item(s)
Cell Source Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsCellsTags (6)
immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companiesGeographic Markets
United StatesCell Source Financials
$21.54M
Total funding
—
Capital raised
$21.54M
Last funding
Public
Funding stage
1
Total rounds
0
Investors
Public Offering / Exit
POEvent
May 2014
Undisclosed
Cell Source Lifecycle
All Events
POEvent
May 2014
Undisclosed
Cell Source News
2 articles
growth-positive
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Cell Source, Inc. presented promising preclinical findings at the 2024 American Society of Hematology Annual Meeting, showcasing their Veto Cell technologys ability to overcome NK cell-mediated rejection, a significant barrier in allogeneic cell therapy. This innovation could lead to safer, less costly, and more scalable off-the-shelf CAR-T therapies. The study demonstrated that Veto Tcm cells can suppress NK cell activity without adverse effects, enhancing the safety and efficacy of allogeneic CAR-T therapies. These findings align with Cell Sources vision of advancing immune tolerance to facilitate safer mismatched donor stem cell transplants and organ transplantation. The research represents a significant step towards overcoming challenges in developing off-the-shelf CAR-T cell therapies, a critical area in cancer immunotherapy.
growth-positive
Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial
Cell Source, Inc. announced positive interim results from its Phase 1/2 clinical trial using its Veto Cell technology for stem cell transplants. Conducted at The University of Texas MD Anderson Cancer Center, the trial involved 15 patients and demonstrated both safety and efficacy, with no severe graft-versus-host disease or toxicity linked to Veto Cells. This breakthrough suggests a safer, more patient-friendly approach to stem cell therapy, potentially transforming treatment for various hematologic conditions. The results were previously presented at the American Society for Hematology Annual Meeting. The findings highlight the potential of Veto Cells to improve access to life-saving transplants, aligning with the strategic goals of Cell Source. The success in this area mirrors the market potential seen in companies like Kite Pharma and Juno Therapeutics, which were acquired for substantial amounts following similar clinical achievements.
Employee Info
| Employees (range) | 11-50 |
| Exact count | 20 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Cell Source Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 88/100 |
| Missing | funding rounds, markets, external profiles, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514669761 |
| Crunchbase | cell-source |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-08-23T00:00:00.000Z |
| Created | 2014-07-30T00:00:00.000Z |
| Status detail | Public on OTC on May, 2014; |